From the Editor

TON September 2015 Vol 8 No 5
Beth Faiman, PhD, APRN-BC, AOCN
Founding Editor in Chief

In this month’s issue of The Oncology Nurse-APN/PA (TON), we wrap up our coverage of the news from the recent Oncology Nursing Society (ONS) 40th Annual Congress and the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO).

At ONS, Anne Katz, RN, PhD, discussed how young adults with cancer are a unique population with special needs. She noted, “Three things are important in dealing with them: communication, communication, communication.” Mariana Chavez-MacGregor, MD, informed listeners that approximately 40% of patients with breast cancer treated with anthracyclines do not receive NCCN guideline–adherent prophylaxis for chemotherapy-induced vomiting. Laurie Farrell, NP, addressed nurses and advanced nurse practitioners about management options with obinutuzumab for patients with chronic lymphocytic leukemia.

Be sure to read our cancer center profile with Kathy Wilkinson, RN, BSN, OCN. Then pick up your copy of the TON July issue or go to the TON website (www.TheOncologyNurse.com) to get more information about Kathy’s ONS poster presentation on a strategy that utilized a dyad of disease-specific clinical trial nurses and disease-specific nurse navigators to boost enrollment in clinical trials at the Billings Clinic Cancer Center.

Our ASCO coverage includes a discussion of the basics of immunotherapy, including treatment response patterns, mechanisms of action, and management of side effects. We also present an interview with Jennifer Temel, MD, who talks about the potential role of anamorelin, a drug in phase 3 clinical trials. Anamorelin may help patients increase lean body mass and body weight.

October is National Breast Cancer Awareness Month. In Noteworthy Numbers, we present some information about a few organizations that sponsor programs in support of breast cancer, education, treatment, and research. Cristi Radford, in her Genetic Counseling column, updates readers about the research involving RECQL, which appears to be a new breast cancer susceptibility gene.

As always, we at TON want to hear about your ideas and opinions. Please be sure to visit our website, www.TheOncologyNurse.com, and tell us what topics you want to see covered in TON. We love to hear from you and we appreciate your feedback.

Related Items


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: